KAZUMI SHIOSAKI
Managing Partner at MPM Capital
About
Kazumi Shiosaki is a Managing Partner at MPM Capital, a prominent venture capital firm dedicated to life sciences. She focuses on identifying and investing in groundbreaking biotech companies, particularly those developing novel therapeutics. Her expertise lies in company creation and early-stage investments, contributing significantly to advancements in the biopharmaceutical sector.
Recent News & Mentions
Experience
Deep Dive
Kazumi Shiosaki stands as a distinguished Managing Partner at MPM Capital, a leading venture capital firm renowned for its deep commitment to advancing life sciences. At MPM Capital, Kazumi plays a critical role in shaping the future of medicine by identifying, funding, and nurturing innovative biotechnology companies. Her investment focus is primarily on novel therapeutics, spanning critical areas such as oncology, immunology, and rare diseases, where there remains significant unmet medical need.
Her strategic vision and deep industry knowledge are instrumental in MPM Capital's success in company creation. Kazumi is actively involved in building companies from the ground up, working closely with scientific founders and management teams to translate cutting-edge research into viable therapeutic solutions. This hands-on approach ensures that portfolio companies are well-positioned for success, from early-stage development through clinical trials and beyond.
Before joining MPM Capital in 2005, Kazumi honed her expertise in various capacities within the life sciences investment landscape. She served as a Principal at Bay City Capital, where her focus was on private equity investments across the life sciences sector. Prior to her venture capital roles, Kazumi was a consultant at McKinsey & Company, providing strategic guidance to pharmaceutical and biotechnology companies on complex business challenges. This diverse background equipped her with a comprehensive understanding of both the scientific and commercial aspects of drug development.
Kazumi's academic foundation is equally robust, holding an MBA from Stanford University Graduate School of Business and a BA in Chemistry from Princeton University. Her blend of scientific acumen and business insight makes her a formidable force in the venture capital world.
Throughout her tenure at MPM Capital, Kazumi Shiosaki has been a key driver in numerous successful investments and company builds. Her board roles have included influential companies such as Werewolf Therapeutics (NASDAQ: HOWL), Orna Therapeutics, ReNAgade Therapeutics, ElevateBio, Triplet Therapeutics, and NextPoint Therapeutics. She was also instrumental in the success of Maverick Therapeutics (acquired by Takeda), Potenza Therapeutics (acquired by Astellas), and TCR2 Therapeutics (acquired by Adaptimmune), demonstrating her ability to identify and scale companies that deliver significant value and therapeutic impact. Her leadership continues to propel MPM Capital's mission to invest in transformative biomedical innovation.
Frequently Asked Questions
Who is Kazumi Shiosaki?
Kazumi Shiosaki is a Managing Partner at MPM Capital, a prominent venture capital firm specializing in life sciences and biotech investments.
What does Kazumi Shiosaki invest in?
Kazumi Shiosaki primarily invests in groundbreaking biotech companies focused on novel therapeutics, particularly in areas like oncology, immunology, and rare diseases. She is also deeply involved in company creation and early-stage investments.
Where does Kazumi Shiosaki work?
Kazumi Shiosaki works as a Managing Partner at MPM Capital, a leading venture capital firm dedicated to advancing life sciences.